Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CK3" target="_blank" >RIV/61988987:17110/21:A2202CK3 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/20:A22027HT
Result on the web
<a href="http://dx.doi.org/10.1111/bjh.17235" target="_blank" >http://dx.doi.org/10.1111/bjh.17235</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.17235" target="_blank" >10.1111/bjh.17235</a>
Alternative languages
Result language
angličtina
Original language name
Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2020
Original language description
Remarkable advances have been achieved in the treatment of multiple myeloma (MM) in the last decade, which saw targeted immunotherapy, represented by anti-CD38 monoclonal antibodies, successfully incorporated across indications. However, myeloma is still considered curable in only a small subset of patients, and the majority of them eventually relapse. B-cell maturation antigen (BCMA) is expressed exclusively in mature B lymphocytes and plasma cells, and represents an ideal new target for immunotherapy, presented by bispecific antibody (bsAb) constructs, antibody-drug conjugates (ADCs) and chimeric antigen receptor T (CAR-T) cells. Each of them has proved its efficacy with the potential for deep and long-lasting responses as a single agent therapy in heavily pretreated patients. As a result, belantamab mafodotin was approved by the United States Food and Drug Administration for the treatment of relapsed/refractory MM, as the first anti-BCMA agent. In the present review, we focus on monoclonal antibodies targeting BCMA – bsAbs and ADCs. The data from preclinical studies as well as first-in-human clinical trials will be reviewed, together with the coverage of their constructs and mechanisms of action. The present results have laid the groundwork for the ongoing or upcoming clinical trials with combinatory regimens, which have always been a cornerstone in the treatment of MM.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
O - Projekt operacniho programu
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
BRITISH JOURNAL OF HAEMATOLOGY
ISSN
0007-1048
e-ISSN
1365-2141
Volume of the periodical
193
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
18
Pages from-to
705-722
UT code for WoS article
000590690800001
EID of the result in the Scopus database
—